Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ADC2122

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Adcoris, Zhejiang Hisun, ZovaBio

Drug class:

HER2-targeted antibody-drug conjugate, Tubulin inhibitor

Related drugs:

‹

paclitaxel liposomal (0)

liposomal paclitaxel (0)

paclitaxel nanoformulation (0)

paclitaxel-hyaluronic acid conjugate (0)

paclitaxel poliglumex (0)

bisphosphonate bound paclitaxel (0)

BAY 59-8862 (0)

ado-trastuzumab emtansine (97)

fam-trastuzumab deruxtecan-nxki (90)

disitamab vedotin (27)

trastuzumab duocarmazine (6)

PF-06804103 (4)

MF-TTZ-MMAE (1)

albumin-bound paclitaxel (67)

micellar paclitaxel (3)

REGN5093-M114 (3)

vinblastine (3)

paclitaxel oral (1)

oral paclitaxel/encequidar (1)

hIMB1636-MMAE (1)

paclitaxel polymeric micelle formulation (0)

paclitaxel liposomal (0)

liposomal paclitaxel (0)

paclitaxel nanoformulation (0)

paclitaxel-hyaluronic acid conjugate (0)

paclitaxel poliglumex (0)

bisphosphonate bound paclitaxel (0)

BAY 59-8862 (0)

›

Sensitive: C2 – Inclusion Criteria

Sensitive: C2 – Inclusion Criteria